Oasis DiagnosticsS.A.
Research and experimental development in natural sciences and engineering
Overview
OASIS Diagnostics SA is a MedTech company focused on women’s health. It develops ONIRY, a one-minute test used right after delivery to detect obstetric anal sphincter injuries (OASI) and assess the risk of fecal incontinence. The system is described as an early postpartum diagnostic tool with a tiny probe for patient comfort.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
Conference in Czech Republic
We are seeing a growing willingness within the Czech obstetrics community to look more closely at how postpartum assessment is carried out in practice.
Symposium in Turkey
We had the pleasure of participating in the Eskişehir Urogynecology Symposium (April 11–12), where our KOL, Dr. Małgorzata Uchman-Musielak, shared clinical insights on the importance of early detection of obstetric anal sphincter injuries (OASI).
Regulatory milestone: our system registered in Turkey
We are pleased to announce that our EU MDR-certified postpartum diagnostic platform has officially completed medical device registration in Turkey, and our Spectrometer and Probe are now fully registered as medical devices in Turkish market!
Postpartum perineal diagnostics is entering public discussion in Central Europe
Last week, Prof. Hynek Herman spoke on Czech national television about the diagnostic challenges in obstetric anal sphincter injuries (OASI) and the potential role of impedance spectroscopy in early detection.
Polish FemTech 2025 Map
We are honoured to have been included in the First Map of Polish Femtech in the Pelvic Floor Health, Pregnancy and Labour category! The link to the LinkedIn post: https://www.linkedin.com/posts/femtech-po-polsku_mapa-polskiego-femtechu-2025-polish-femtech-activity-7404872782502711296-HTsd?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA7X1aEBUORr0zdxvdN8OdK1g6rfDob4A9I
New distribution collaboration in Hungary
We are excited to share that OASIS Diagnostics is starting a new collaboration in Hungary 🇭🇺 with Hueso Medical Kft.
Industry
Bank accounts
Registered as a VAT taxpayer on 2018-03-12. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 18, 2019 | Commercial Companies Code notice |
Public aid
9 public aid cases recorded, with a total value of $1,649,189.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,973$3,973 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 18, 2020 | Aid for SMEs for innovation support | $12,973$12,973 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,973$3,973 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Two members of the management board acting jointly are authorized to make declarations of will on behalf of the company and to represent the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Katarzyna Borycka (53)  | Shareholder of a joint-stock company, 56.43% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | ||
| SatroecgS.A. | $117,301.57 | satroecg.pl | ||
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | ||
| Biostat Research And Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-07-21 | Share capital change (208,409.00 PLN → 208,046.00 PLN) | |
| 2025-05-16 | Share capital change (187,906.00 PLN → 208,409.00 PLN) | |
| 2023-12-07 | Address change (Ul. Gen. Mariana Langiewicza 54, 95-050, Konstantynów Łódzki → Ul. Czerska 8/10/313, 00-732, Warszawa) | |
| 2023-10-18 | Share capital change (158,596.00 PLN → 187,906.00 PLN) | |
| 2023-03-28 | Share capital change (154,461.00 PLN → 158,596.00 PLN) |
FAQ
Last updated: 2026-07-12